phase readout
saveNCT07203001: A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease
RECRUITINGupdated 2mo ago
community read0 votes
Sponsor: Novartis Pharmaceuticals. Phase: PHASE2. Conditions: Still´s Disease
view source ↗
comments(0)
5-min edit window · permanent after that